Table 1

Baseline characteristics of patients with newly diagnosed cancer (n=555)

Patients with cancer (n=555)
Age, years (IQR)62 (52–71)
Male gender, n (%)197 (40%)
BMI kg/m2, (IQR)25.0 (22.6–28.4)
Comorbidities
 Known CAD, n (%)28 (5%)
 Valvular disease, n (%)8 (1%)
 Heart failure, n (%)38 (7%)
 Stroke/TIA, n (%)17 (3%)
 PAD, n (%)19 (3%)
 Diabetes mellitus, n (%)43 (8%)
 Arterial hypertension, n (%)250 (45%)
 CKD, n (%)31 (6%)
 COPD, n (%)113 (20%)
 Currently smoking, n (%)118 (21%)
 Sinus rhythm, n (%)509 (96%)
 PM or ICD, n (%)6 (1%)
Medication
 Beta-blocker, n (%)123 (22%)
 ACE or ARB, n (%)166 (31%)
 Aldosterone antagonist, n (%)15 (3%)
 Digitalis, n (%)3 (1%)
 ASS, n (%)111 (20%)
Planned therapy*383 (89%)
 Surgery, n (%)318 (75%)
 Anticancer chemotherapy, n (%)298 (70%)
 Hormone therapy, n (%)66 (16%)
 Radiation therapy, n (%)146 (34%)
 Antibody therapy, n (%)80 (19%)
 Bone marrow transplantation, n (%)4 (1%)
Normal cardiac status, n (%)408 (75%)
Serum creatinine, mg/dL (IQR)0.88 (0.77–1.03)
GFR, mL/min/1.73 m2 (IQR)74.5 (63.7–86.0)
hsTnT, ng/mL (IQR)0.006 (0.003–0.010)
NT-proBNP, pg/mL (IQR)128 (64–279)
MR-proANP, pmol/L (IQR)66.5 (47.2–107.3)
MR-proADM, nmol/L (IQR)0.56 (0.44–0.72)
CT-proET-1, pmol/L (IQR)52.5 (40.3–68.1)
Copeptin, pmol/L (IQR)4.60 (2.90–8.28)
CRP, mg/L (IQR)0 (0–1)
IL-6, pg/mL (IQR)2 (2–3)
Fibronectin, mg/dL (IQR)42 (35–48)
Haptoglobin, mg/dL (IQR)137 (93–201)
SAA, µg/mL (IQR)8 (4–26)
  • Continuous variables are given as medians and IQR. Counts are given as numbers and percentages.

  • *Information about planned therapy was collected for all patients excluding those with myeloproliferative neoplasias.

  • ARB, angiotensin receptor blocker; ASS, acetyl salicylic acid; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; CT-proET-1, C-terminal pro endothelin-1; GFR, glomerular filtration rate; hsTnT, high-sensitive troponin T; ICD, implantable cardioverter defibrillator; IL-6, interleukin 6; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAD, peripheral artery disease; PM, pacemaker; SAA, serum amyloid A; TIA, transitory ischaemic attack.